Jeffery Morrow
Optometrist · Mobile, ALNPI 1437120219
Payments from drug & device makers
Across 40 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$295
- Tarsus Pharmaceuticals, Inc.$180
- Bausch & Lomb, A Division Of Bausch Health US, LLC$100
- Dompe US, Inc.$89
- Oyster Point Pharma, Inc.$82
- Aerie Pharmaceuticals, Inc.$43
- plus $106 from 4 others
What the payments were for
- Food & beverage$87698%
- Education$182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 12 | $295 |
| Tarsus Pharmaceuticals, Inc. | 9 | $180 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $100 |
| Dompe US, Inc. | 3 | $89 |
| Oyster Point Pharma, Inc. | 3 | $82 |
| Aerie Pharmaceuticals, Inc. | 2 | $43 |
| Bausch & Lomb Americas Inc. | 2 | $34 |
| Merz Pharmaceuticals, LLC | 1 | $34 |
| Alcon | 1 | $24 |
| Amgen | 1 | $15 |
How this compares
$894 in reported general payments places this provider in the 45th percentile of 749 optometrist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 52 | $21,941 |
| RestasisCyclosporine | 16 | $14,290 |
| Brimonidine Tartrate | 13 | $1,863 |
| Prednisolone Acetate | 39 | $1,810 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 27 | $1,369 |
| Latanoprost | 93 | $1,128 |
| Timolol Maleate | 77 | $948 |
| ErythromycinErythromycin Base | 48 | $578 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 36 | $491 |
| Doxycycline Hyclate | 27 | $485 |
| ValacyclovirValacyclovir Hcl | 13 | $414 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $328 |
| Prednisone | 12 | $62 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Mobile
- Mark ShireyMobile$16K
- Andrew PuckerBirmingham$667K
- Mark SchaefferHoover$473K
- Kelly NicholsBirmingham$298K
- Benjamin KachelmanFlorence$102K
- Natalie WestBirmingham$85K
- Katherine WeiseBirmingham$82K
- Neena JamesHuntsville$74K
- Tracey Schroeder SwartzHuntsville$69K
- Jack SchaefferHoover$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.